Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Dec 12, 2023

BUY
$36.12 - $47.5 $448,899 - $590,330
12,428 New
12,428 $497,000
Q2 2023

Aug 08, 2023

SELL
$36.12 - $47.5 $304,491 - $400,425
-8,430 Reduced 40.42%
12,428 $497,000
Q1 2023

Dec 12, 2023

BUY
$35.53 - $43.38 $441,566 - $539,126
12,428 New
12,428 $507,000
Q4 2022

Feb 03, 2023

BUY
$38.19 - $57.45 $2,062 - $3,102
54 Added 0.26%
20,858 $805,000
Q2 2022

Aug 09, 2022

BUY
$51.49 - $81.64 $4,376 - $6,939
85 Added 0.41%
20,804 $1.21 Million
Q4 2021

Feb 02, 2022

SELL
$47.97 - $62.21 $3,261 - $4,230
-68 Reduced 0.33%
20,719 $1.25 Million
Q3 2021

Oct 26, 2021

BUY
$54.64 - $61.3 $264,840 - $297,121
4,847 Added 30.41%
20,787 $1.16 Million
Q2 2021

Jul 27, 2021

SELL
$59.18 - $69.99 $591 - $699
-10 Reduced 0.06%
15,940 $967,000
Q1 2021

Apr 27, 2021

SELL
$59.31 - $78.82 $93,828 - $124,693
-1,582 Reduced 9.02%
15,950 $1.12 Million
Q4 2020

Jan 29, 2021

BUY
$50.47 - $66.26 $98,315 - $129,074
1,948 Added 12.5%
17,532 $1.05 Million
Q3 2020

Nov 10, 2020

SELL
$51.97 - $63.0 $362,126 - $438,984
-6,968 Reduced 30.9%
15,584 $937,000
Q2 2020

Aug 07, 2020

SELL
$30.8 - $52.47 $109,802 - $187,055
-3,565 Reduced 13.65%
22,552 $1.18 Million
Q1 2020

Apr 28, 2020

SELL
$28.4 - $50.7 $2,243 - $4,005
-79 Reduced 0.3%
26,117 $876,000
Q4 2019

Feb 12, 2020

SELL
$36.31 - $46.83 $163,685 - $211,109
-4,508 Reduced 14.68%
26,196 $1.19 Million
Q3 2019

Oct 29, 2019

BUY
$35.66 - $44.99 $850,704 - $1.07 Million
23,856 Added 348.36%
30,704 $1.17 Million
Q1 2018

Apr 19, 2018

BUY
$29.98 - $46.35 $46,948 - $72,584
1,566 Added 29.65%
6,848 $213,000
Q4 2017

Jan 24, 2018

BUY
$31.85 - $46.95 $168,231 - $247,989
5,282
5,282 $241,000

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $892M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track Ken Fisher's Portfolio

Track Ken Fisher Portfolio

Follow Ken Fisher (Fisher Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.